TOPPER IAS
Login Talk to a mentor

← 4 November 2026's Current Affairs · Science & Tech GA Prelims ★★★☆☆ Mains ★★☆☆☆

Quick scan: BIRSA-101 gene therapy targets sickle cell disease and beta thalassaemia

4 November 2026 · ⏱ 2 મિનિટ · GS3: Biotechnology, health

1

સમાચારમાં કેમ?

Why is India's CRISPR therapy named after Birsa Munda? The sickle cell and thalassaemia facts GS3 tests

BIRSA-101 is a CRISPR-based therapy for sickle cell disease and beta thalassaemia.

Why it matters: general awareness

Quick scan: BIRSA-101 gene therapy targets sickle cell disease and beta thalassaemia
R Ashwani Banjan Murmu · CC BY-SA 4.0 · Wikimedia Commons
2

What you need to know

2 મિનિટ

BIRSA-101 is an Indian CRISPR-based gene therapy aimed at sickle cell disease and beta thalassaemia, two inherited blood disorders.

It is named after the tribal leader Birsa Munda and is a step towards affordable indigenous gene editing.

સ્રોત: Topper IAS editorial (PIB / The Hindu / Indian Express)

3

મુખ્ય તથ્યો

Remember these

  • BIRSA-101 is an Indian CRISPR-based gene therapy for sickle cell disease and beta thalassaemia.
  • Both are inherited blood disorders linked to defects in the haemoglobin beta-globin (HBB) gene.
  • The therapy is named after tribal leader Birsa Munda, a nod to sickle cell's burden among tribal communities.
  • CRISPR-Cas9 earned the 2020 Chemistry Nobel for Emmanuelle Charpentier and Jennifer Doudna.
  • The National Sickle Cell Anaemia Elimination Mission was launched in 2023.
4

પ્રિલિમ્સ · મેઇન્સ

How the exam will ask it

પ્રિલિમ્સ

  • CRISPR-Cas9 is a genome-editing tool that uses guide RNA to direct the Cas9 nuclease to a specific DNA sequence.
  • Sickle cell disease and beta thalassaemia are inherited (autosomal recessive) haemoglobinopathies, not infectious diseases.
  • Gene therapy modifies or edits a patient's genes to treat disease, unlike conventional drugs that manage symptoms.

મેઇન્સ

GS3 (Science and Technology, Biotechnology, Health): India's genetic disease burden, especially among tribal populations, makes affordable indigenous gene editing important. Policy support runs through the Sickle Cell Elimination Mission and public research bodies, but costs, clinical-trial safety, regulation and ethics of germline editing remain concerns. The way forward is rigorous trials, a clear regulatory framework, screening and counselling, and public financing so that access is equitable.

5

Quick recall

Answer before you reveal

    જવાબ જુઓ

    જવાબ: —

    6

    Convert this topic into marks

    Today's 10-MCQ test · instant analysis · Powered by AdaptIQ

    DONE READING?

    Test today's current affairs.